LifeTech Scientific Corp
HKEX:1302
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (24.7), the stock would be worth HK$1.39 (26% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 33.3 | HK$1.88 |
0%
|
| 3-Year Average | 24.7 | HK$1.39 |
-26%
|
| 5-Year Average | 25.6 | HK$1.44 |
-23%
|
| Industry Average | 26.2 | HK$1.48 |
-21%
|
| Country Average | 28.8 | HK$1.63 |
-13%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
HK$8.4B
|
/ |
Jan 2026
¥216.4m
|
= |
|
|
HK$8.4B
|
/ |
Dec 2026
¥576.7m
|
= |
|
|
HK$8.4B
|
/ |
Dec 2027
¥626.7m
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
LifeTech Scientific Corp
HKEX:1302
|
8.9B HKD | 33.3 | 51.4 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
170B USD | 45.1 | 59.5 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
160.6B USD | 14 | 25.6 | |
| US |
|
Stryker Corp
NYSE:SYK
|
126.1B USD | 19.9 | 38.8 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
107.5B USD | 12.9 | 23.3 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
97.4B USD | 19.9 | 33.6 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
40.6B EUR | 10.8 | 19.2 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
46.3B USD | 23.4 | 43.1 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
44.7B USD | 29.9 | 42.2 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
44.1B USD | 10 | 25.1 | |
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
31.9B USD | 11.1 | 15.3 |
Market Distribution
| Min | 0 |
| 30th Percentile | 16.3 |
| Median | 28.8 |
| 70th Percentile | 53.1 |
| Max | 49 021 |
Other Multiples
LifeTech Scientific Corp
Glance View
LifeTech Scientific Corp. is an investment holding company, which engages in the development, manufacture, research, development and market of minimally invasive medical devices for cardiovascular and peripheral vascular diseases and disorders. The company is headquartered in Shenzhen, Guangdong and currently employs 943 full-time employees. The company went IPO on 2011-11-10. The firm operates through three business segments. The Congenital Heart Diseases Business segment is engaged in the research and development, manufacture and trading of devices related to congenital and structural heart diseases. The Peripheral Vascular Diseases Business segment is engaged in the research and development, manufacture and trading of devices related to peripheral vascular diseases. The Surgical Vascular Repair Business segment is engaged in the research and development, manufacture and trading of devices related to surgical vascular repair.
